Constellation Pharma Raises $15M for Epigenetic Drugs

6/6/11

Cambridge, MA-based Constellation Pharmaceuticals said today it has raised $15 million in a Series B extension from its existing investors, including Third Rock Ventures, The Column Group, Venrock Associates, SR One, and Altitude Life Science Ventures. Constellation, whose Series B now totals $37 million (after a $32 million A round in 2008-09) is working to develop drugs for treating cancer, inflammatory and immunologic disorders, and other diseases. The company’s technology is based on epigenetics, the study of molecular changes in cells that can turn certain genes on and off without changing the underlying DNA code. Constellation is led by CEO Mark Goldsmith, who spoke with Xconomy back in 2009 after taking over from founding CEO Mark Levin, the former Millennium Pharmaceuticals boss and co-founder of Third Rock.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com. Follow @

By posting a comment, you agree to our terms and conditions.